BridgeBio Oncology Therapeutics, Inc. Proceeds from Sale and Maturity of Marketable Securities
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported Proceeds from Sale and Maturity of Marketable Securities of $79.58 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-08-11
- BridgeBio Oncology Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2026-06-30 was $53.31M, a 21.57% increase year-over-year.
- BridgeBio Oncology Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2026-03-31 was $26.26M, a 34.28% decline year-over-year.
- BridgeBio Oncology Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-12-31 was $28.88M, a 12.97% increase year-over-year.
- BridgeBio Oncology Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2025-09-30 was $45.16M.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $53.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $79.58M 10-Q · filed 2026-08-11 | $108.46M derived: sum of 3 quarters · filed 2026-08-11 | $153.62M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $26.26M 10-Q · filed 2026-05-12 | $55.15M derived: sum of 2 quarters · filed 2026-05-12 | $100.30M derived: sum of 3 quarters · filed 2026-05-12 | $144.16M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $28.88M derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-30 | $74.04M derived: sum of 2 quarters · filed 2026-04-30 | $117.90M derived: sum of 3 quarters · filed 2026-08-11 | $157.86M POS AM · filed 2026-04-30 |
| 2025-09-30 | $45.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $89.01M derived: sum of 2 quarters · filed 2026-08-11 | $128.98M 10-Q · filed 2025-11-12 | $154.54M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $43.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $83.82M 10-Q · filed 2026-08-11 | $109.38M derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-03-31 | $39.96M 10-Q · filed 2026-05-12 | $65.53M derived: sum of 2 quarters · filed 2026-05-12 | ||
| 2024-12-31 | $25.57M derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-30 | $31.54M POS AM · filed 2026-04-30 | ||
| 2024-09-30 | $5.98M 10-Q · filed 2025-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |